Calcium antagonists for Duchenne muscular dystrophy

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2008, Pages

  Phillips, Margaret F ^a   Quinlivan, Rosaline ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b ROBERT JONES AND AGNES HUNT ORTHOPAEDIC HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BIOCHEMICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; DANTROLENE; DILTIAZEM; FLUNARIZINE; NICARDIPINE; NIFEDIPINE; PLACEBO; VERAPAMIL;

CARDIOTOXICITY; CLINICAL EXAMINATION; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FATALITY; DRUG SCREENING; DRUG WITHDRAWAL; DUCHENNE MUSCULAR DYSTROPHY; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; EMBASE; ERGOMETRY; FLUSHING; FUNCTIONAL ASSESSMENT; GINGIVA HYPERPLASIA; HEADACHE; HUMAN; LEG SWELLING; LUNG FUNCTION TEST; MEDLINE; META ANALYSIS; METHODOLOGY; MUSCLE FORCE; MUSCLE FUNCTION; MUSCLE STRENGTH; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PR INTERVAL; PULSE RATE; RACING PULSE; RASH; REVIEW; SCORING SYSTEM; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 55049118484     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004571.pub2     Document Type: Review

References (66)

1. Dick 1986 {published data only} Dick D, Gardner-Medwin D, Gates P, Gibson M, Simpson J, Walls T. A trial of flunarizine in the treatment of Duchenne Muscular Dystrophy. Muscle and Nerve 1986;9:349-54.
2. Emery 1983 {published data only} * Emery A, Skinner R. Double blind controlled trial of a calcium blocker in Duchenne Muscular Dystrophy. Cardiomyology 1983;2:13-23.
3. Emery AEH, Skinner R, Howden LC, Matthews MB. Verapamil in Duchenne muscular dystrophy. Lancet 1982;319(8271):559.
4. Moxley 1987 {published data only} Moxley RT, Brooke MH, Fenichel GM, Mendell J, Griggs R, Miller P, et al.Clinical investigation in Duchenne dystrophy. VI Double blind controlled trial of nifedipine. Muscle & Nerve 1987;10(1):22-33.
5. Pernice 1988 {published data only} Pernice W, Beckmann R, Ketelsen U-P, Frey M, Schmidt-Redemann B, Haap KP, et al.A double blind placebo controlled trial of diltiazem in Duchenne dystrophy. Klinische Wochenschrift 1988;66(13):565-70.
6. Toifl 1991 {published data only} Toifl K, Presterl E, Graninger W. Lack of effect of diltiazem in the treatment of Duchenne's muscular dystrophy: a double blind placebo controlled study [Fehlende Wirksamkeit von Diltiazem bei Duchenne-Muskeldystrophie: eine placebo-kontrollierte Doppelblindstudie]. Wiener klinische Wochenschrift 1991;103(8): 232-5.
7. Bertorini 1988 {published data only} Bertorini TE, Palmieri GMA, Griffin JW, Igarishi M, McGee J, Brown R, et al.Effect of chronic treatment with calcium antagonist diltiazem in Duchenne muscular dystrophy. Neurology 1988;38(4):609-13.
8. Bertorini 1991 {published data only} Bertorini TE, Palmieri GMA, Griffin J, Igarishi M, Hinton A, Karas JG. Effect of dantrolene in Duchenne muscular dystrophy. Muscle & Nerve 1991;14(6):503-7.
9. Garcia 1990 {published data only} Garcia AM, Goldemberg AL, Fernandez H, Fortunato M, Ricci L, Trucco RE. Effect of chronic administration of verapamil in Duchenne muscular dystrophy. General Pharmacology 1990;21(6):939-42.
10. Anand 1980 Anand R, Emery AE. Calcium-stimulated enzyme efflux from human skeletal muscle. Research communications in chemical pathology and pharmacology 1980;28(3):541-50.
11. Archibald 1959 Archibald KC, Vignos PJ. A study of contractures in muscular dystrophy. Archives of Physical Medicine 1959;40(4):150- 7.
12. Biggar 2006 Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular Disorders 2006;16:249-255.
13. Bodensteiner 1978 Bodensteiner JB, Engel AG. Intracellular calcium accumulation in Duchenne dystrophy and other myopathies. Neurology 1978;28(5):439-46.
14. Bonilla 1988 Bonilla E, Samitt CE, Miranda AF, Hays AP, Salviati G, DiMauro S, et al.Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. Cell 1988;54(4):447-52.
15. Brooke 1981 Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle & Nerve 1981;4(3):186-97.
16. Chang 1988 Chang CC, Lin SO, Hong SJ, Chiou LC. Neuromuscular block by verapamil and diltiazem and inhibtion of acetylcholine release. Brain Research 1988;454(1-2):332-9.
17. Cohn 2001 Cohn RD, Durbeej M, Moore SA, Coral-Vazquez R, Prouty S, Campbell KP. Prevention of cardiomyopathy in mouse models lacking the sarcoglycan-sarcospan complex. The Journal of Clinical Investigation 2001;107(2):153-4.
18. Cornelio 1984 Cornelio F, Dworzak F, Morandi L. Therapeutic trials in Duchenne Muscular Dystrophy. Italian Journal of Neurological Sciences 1984;S3:133-6.
19. Cullen 1975 Cullen MJ, Fulthorpe JJ. Stages in fibre breakdown in Duchenne muscular dystrophy: an electron-microscopic study. Journal of the Neurological Sciences 1975;24(2):179-200.
20. Danialou 2001 Danialou G, Comtois AS, Dudley R, Karpati G, Vincent G, Des Rosiers C, et al.Dystrophin deficient cardiomyocytes are abnormally vulnerable tomechanical stress-induced contractile failure and injury. FASEB Journal 2001;15(9):1655-7.
21. Dickersin 1994 Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. British Medical Journal 1994;309(6964):1286-91.
22. Eagle 2002 Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscular Disorders 2002;12(10):926-9.
23. Elsheikh 2007 Elsheikh BH, Bollman E, Peruggia M, King W, Galloway G, Kissel JT. Pilot trial of diltiazem in facioscapulohumeral muscular dystrophy. Neurology 2007;68(17):1428-9.
24. Figulla 1996 Figulla HR, Gietzen F, Zeymer U, Raiber M, Hegselmann J, Soballa R, et al.Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the diltiazem in dilated cardiomyopathy trial. Circulation 1996;94(3):346-52.
25. Fong 1990 Fong PY, Turner PR, Denetclaw WF, Steinhardt RA. Increased activity of calcium leak channels in myotubes of Duchenne human and mdx mouse origin. Science 1990;250(4981):673-6.
26. Gilroy 1963 Gilroy J, Cahalan JL, Berman R, Newman M. Cardiac and pulmonary complications in Duchenne's progressive muscular dystrophy. Circulation 1963;27(4 Pt 1):484-93.
27. Hernandez 1999 Hernandez-Hernandez R. Effects of amlodipine and enelapril on platelet function in patients with mild to moderate hypertension. International journal of clinical pharmacology and therapeutics 1999;37(7):323-31.
28. Hudecki 1984 Hudecki MS, Pollina CM, Heffner RR. In vivo effects of three calcium blockers on chickens with inherited muscular dystrophy. Experimental Neurology 1984;84(3):512-23.
29. Ibraghimov 1992 Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett SW, Campbell KP. Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature 1992;355(6362):696-702.
30. Iwata 2003 Iwata Y, Katanosaka y, Arai Y, Komamura K, Miyatake K, Shigekawa M. A novel mechanism of myocyte degeneration involving the Ca2+-permeable growth factor regulated channel. Journal of Cell Biology 2003;161(5):957-67.
31. Jackson 1991 Jackson MJ, McArdle A, Edwards RHT. Free radicals, calcium and damage in dystrophic and normal skeletal muscle. In Calcium free radicals and tissue damage. Cambridge: Cambridge University Press, 1991:pp139-48..
32. Jadad 1996 Jadad A, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
33. Johnson 1993 Johnson PL, Bhattacharya SK. Regulation of membrane-mediated chronic muscle degeneration in dystrophic hamsters by calcium channel blockers: diltiazem, nifedipine and verapamil. Journal of the Neurological Sciences 1993;115(1):76-90.
34. Jones 1984 Jones DA, Jackson MJ, McPhail G, Edwards RHT. Experimental mouse muscle damage: the importance of external calcium. Clinical Science 1984;66(3):317-22.
35. Koenig 1987 Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987;50(3):509-17.
36. Kumar 2004 Kumar A, Khandelwal N, Malya R, Reid MB. Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibres. The FASEB journal 2004;18(1):102-13.
37. Mallouk 2000 Mallouk N, Jacquemond V, Allard B. Elevated subsarcolemmal Ca2+ in mdx mouse skeletal muscle fibres detected with Ca2+ activated K+ channels. Proceedings of the National Academy of Sciences of the United States of America 2000;97(9):4950-5.
38. Manzur 2008 Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database of Systematic Reviews 2008, Issue (1):CD003725.[Art. No.: CD003725. DOI: 10.1002/14651858.CD003725.pub3]
39. Mariol 2001 Mariol M-C, Segalat L. Muscular degeneration in the absence of dystrophin is a calcium-dependent process. Current biology 2001;11(21):1691-4.
40. Markham 2008 Markham LW, Kinnett K, Wong BL, Woodrow Benson D, Cripe L. Corticosteroid treatment retards developiment of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscular disorders 2008;18:365-370.
41. Mason 1999 Mason RP, Walter MF, Trumbore MW, Olmstead EG jr, Mason PE. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. Journal of molecular and cellular cardiology 1999;31(1):275-81.
42. Melacini 1986 Melacini P, Fasoli G, Mammola C, Angelini C, DallaVolta S.Cardiac complications during a trial with a calcium antagonist in a boy with Duchenne muscular dystrophy. Cardiomyology 1986;5(1):39- 47.
43. Miyatake 1989 Miyatake M, Miike T, Zhao JE, Yoshioka K, Uchino M, Tuki G. Possible systemic smooth muscle layer dysfunction due to a deficiency of dystrophin in Duchenne muscular dystrophy. Journal of the Neurological Sciences 1989;93(1):11-17.
44. Moens 1993 Moens P, Baatsen PH, Marechal G. Increased susceptibility of EDL muscles from mdx miceto damage induced by contractions with stretch. Journal of Muscle Research and Cell motility 1993;14(4):446-51.
45. Mohamed 2000 Mohamed K, Appleton R, Nicolaides P. Delayed diagnosis of Duchenne muscular dystrophy. European Journal of Paediatric Neurology 2000;4(5):219-23.
46. MRC 1976 Medical Research Council. Aids to the investigation of peripheral nerve injuries. London: HMSO, 1976.
47. Neglia 2000 Neglia D, Sambuceti G, Giorgetti A, Bartoli M, Salvadori P, Sorace O, et al.Effects of long-term treatment with verapamil on left ventricular function and myocardial bloodflow in patients with dilated cardiomyopathy without overt heart failure. Journal of Cardiovascular Pharmacology 2000;36(6):744-50.
48. Nigro 1990 Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. International Journal of Cardiology 1990;26(3):271-7.
49. O'Connor 1999 O'Connor CM, Radensky PW, Unger AN, Martin BC. Hospital use and costs among patients with nonischemic cardiomyopathy in the first prospective randomized amlodipine survival evaluation study. Clinical Therapeutics 1999;21(7):1254-65.
50. Oberc 1977 Oberc MA, Engel WK. Ultrastructural localization of calcium in normal and abnormal skeletal muscle. Laboratory Investigation 1977;36(6):566-77.
51. Ozkul 2007 Ozkul Y. Influence of calcium channel blocking drugs in neuromuscular transmission. Clinical Neurophysiology 2007;118(9):2005-8.
52. Packer 1996 Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al.Effect of amlodipine on morbidity and mortality in severe chronic heart failure. New England Journal of Medicine 1996;335(15):1107-14.
53. Petrof 1993 Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proceedings of the National Academy of Sciences of the USA 1993;90(8):3710-14.
54. Porter 2002 Porter GA, Makuck RF, Rivkees SA. Reduction in intracellular calcium levels inhibits myoblast differentiation. Journal of Biological Chemistry 2002;277(32):28942-7.
55. Rideau 1983 Rideau Y. Prolongation of life in Duchenne's muscular dystrophy. Acta Neurologica 1983;5(2):118-24.
56. Roed 1991 Roed A. Selective potentiation of subtetanic and tetanic contractions by the calcium-channel antagonist nifedipine in the rat diaphragm preparation. General Pharmacology 1991;22(2):313-18.
57. Schulz 2002 Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet 2002;359(9306):614-8.
58. Scott 1982 Scott OM, Hyde SA, Goddard C, Dubowitz V. Quantitation of muscle function in children: a prospective study in Duchenne muscular dystrophy. Muscle & Nerve 1982;5(4):291-301.
59. Sun 1995 Sun J, Triggle DJ. Calcium channel antagonists: cardiovascular selectivity of action. Journal of pharmacology and experimental therapeutics 1995;274(1):419-26.
60. Turner 1991 Turner PR, Fong PY, Denetclaw WF, Steinhardt RA. Increased calcium influx in dystrophic muscle. Journal of Cell Biology 1991;115(6):1701-12.
61. Turturro 2005 Turturro F, Rocca B, Gumina S, de Cristofaro R, Mangiola F, Maggiano N, et al.Impaired primary hemostatsis with normal platelet function in Duchenne muscular dystrophy during highly-invasive spinal surgery. Neuromuscular Disorders 2005;15(8):532-40.
62. Van Essen 1997 Van Essen AJ, Verhij JBGM, Reefhuis J, Fidler V, Begeer JH, de Visser M, et al.The natural history of Duchenne muscular dystrophy. Analysis of data from Dutch survey and review of age related events [PhD thesis] 1997; Vol. Chapter 3:49-68. [: ISBN 90 367 0711]
63. Vandebrouck 2002 Vanderbrouck C, Martin D, Colson-Van Schoor M, Debaix H, Gailly P. Involvement of TRPC in the abnormal calcium influx observed in dystrophic (mdx)mouse skeletal muscle fibers. Journal of Cell Biology 2002;158(6):1089-96.
64. Wijeysundera 2003 Wijeysundera HC, Hansen MS, Stanton E, Cropp AS, Hall C, Dhalla NS, et al.Neurohormones and oxidative stress in nonischemic cardiomyopathy: relationship to survival and the effect of treatment with amlodipine. American Heart Journal 2003;146(2):291-7.
65. Zalman 1983 Zalman F, Perloff JK, Durant NN, Campion DS. Acute respiratory failure following intravenous verapamil in Duchenne's muscular dystrophy. American Heart Journal 1983;105(3):510-11.
66. Zubrzycka-Gaarn 1988 Zubrzycka-Gaarn EE, Bulman DE, Karpati G, Burghes AH, Belfall B, Klamut HJ, et al. The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature 1988;333(6172):466-9.